1. Home
  2. LAW vs AKBA Comparison

LAW vs AKBA Comparison

Compare LAW & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$3.76

Market Cap

220.0M

Sector

Technology

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.14

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
AKBA
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.0M
251.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
LAW
AKBA
Price
$3.76
$1.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$8.00
$4.67
AVG Volume (30 Days)
245.0K
5.6M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
22.58
93.94
EPS
N/A
N/A
Revenue
$156,849,000.00
N/A
Revenue This Year
$11.23
N/A
Revenue Next Year
$10.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.29
N/A
52 Week Low
$2.45
$0.82
52 Week High
$9.11
$4.08

Technical Indicators

Market Signals
Indicator
LAW
AKBA
Relative Strength Index (RSI) 51.98 57.95
Support Level $3.32 $0.85
Resistance Level $3.84 $1.56
Average True Range (ATR) 0.20 0.09
MACD 0.04 0.03
Stochastic Oscillator 79.84 66.83

Price Performance

Historical Comparison
LAW
AKBA

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: